OBA, M., CHIN, K., KAWAZOE, Y., TAKAGI, K., OGURA, M., SHINOZAKI, E., . . . HATAKE, K. (2011). Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens. D.A. Spandidos.
Style de citation ChicagoOBA, MASARU, et al. Availability of Irinotecan in a Second-line Setting Confers Survival Benefit to Patients With Advanced Gastric Cancer Refractory to Fluoropyrimidine-based Regimens. D.A. Spandidos, 2011.
Style de citation MLAOBA, MASARU, et al. Availability of Irinotecan in a Second-line Setting Confers Survival Benefit to Patients With Advanced Gastric Cancer Refractory to Fluoropyrimidine-based Regimens. D.A. Spandidos, 2011.
Attention : ces citations peuvent ne pas être correctes à 100%.